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Ninjurin1 positively regulates osteoclast
development by enhancing the survival of
prefusion osteoclasts
Sung-Jin Bae1,5, Min Wook Shin1,6, Taekwon Son 1, Hye Shin Lee1, Ji Soo Chae2, Sejin Jeon3, Goo Taeg Oh3 and
Kyu-Won Kim1,4
Abstract
Osteoclasts (OCs) are bone-resorbing cells that originate from hematopoietic stem cells and develop through the
fusion of mononuclear myeloid precursors. Dysregulation of OC development causes bone disorders such as
osteopetrosis, osteoporosis, and rheumatoid arthritis. Although the molecular mechanisms underlying
osteoclastogenesis have been well established, the means by which OCs maintain their survival during OC
development remain unknown. We found that Ninjurin1 (Ninj1) expression is dynamically regulated during
osteoclastogenesis and that Ninj1−/− mice exhibit increased trabecular bone volume owing to impaired OC
development. Ninj1 deﬁciency did not alter OC differentiation, transmigration, fusion, or actin ring formation but
increased Caspase-9-dependent intrinsic apoptosis in prefusion OCs (preOCs). Overexpression of Ninj1 enhanced the
survival of mouse macrophage/preOC RAW264.7 cells in osteoclastogenic culture, suggesting that Ninj1 is important
for the survival of preOCs. Finally, analysis of publicly available microarray data sets revealed a potent correlation
between high NINJ1 expression and destructive bone disorders in humans. Our data indicate that Ninj1 plays an
important role in bone homeostasis by enhancing the survival of preOCs.
Introduction
Bone is a dynamic tissue maintained by continuous
remodeling dependent upon the balance between bone
formation by osteoblasts (OBs) and bone resorption by
osteoclasts (OCs)1. Osteoclasts originate from monocyte/
macrophage precursor cells of myeloid lineage2. In the
bone microenvironment, OC differentiation is mediated
by two essential cytokines, macrophage colony-
stimulating factor (M-CSF) and receptor activator of
nuclear factor κB ligand (RANKL), produced by OBs,
stromal cells, and T lymphocytes3. M-CSF sustains the
survival of OC precursors and mature OCs, and RANKL
promotes OC differentiation via the induction of
NFATc1, a master transcription factor of osteoclasto-
genesis, including differentiation, fusion, maturation,
activation, and survival2–5. Consequently, OCs exhibit
unique morphological features, such as multinucleation,
which is accomplished by the fusion of mononuclear OC
precursor cells, and an actin ring cytoskeleton composed
of podosome belts6,7. Therefore, ﬁne movements and
well-organized actin ring cytoskeletons are prerequisites
not only for cell–cell fusion but also for OC resorptive
function7. Dysregulation of OC development and/or
function leads to pathological bone disorders, such as
osteopetrosis, Paget’s disease, rheumatoid arthritis, and
postmenopausal osteoporosis8–11.
Ninjurin1 (Ninj1) is a transmembrane protein identiﬁed
in neurons and Schwann cells after sciatic nerve injury12.
We previously reported that Ninj1 is expressed in peri-
vascular macrophages near hyaloid vessels and induces
vascular endothelial cell apoptosis via enhanced
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Angiopoietin2 and Wnt7b secretion13. We further
reported that Ninj1 is expressed in myeloid cells, such as
monocytes, macrophages, and microglia, in experimental
autoimmune encephalopathy induced in rat brain and
mouse spinal cord and subsequently modulates inﬂam-
matory myeloid cell inﬁltration14. Ninj1 is also expressed
in monocytes and dendritic cells located in human brain
multiple sclerosis lesions, suggesting that the function of
Ninj1 is conserved in mice and humans15. Additionally,
Ninj1 is upregulated by lipopolysaccharide (LPS) and
regulates LPS-induced inﬂammation in macrophages16,17.
In contrast, the role of Ninj1 in OCs, which are myeloid
lineage descendants, has not yet been elucidated. Here, we
found that Ninj1 is expressed in OCs and is dynamically
regulated during OC differentiation. Ninj1−/− mice show
increased trabecular bone volume related to defective OC
development; additionally, Ninj1 deﬁciency leads to
increased apoptosis in prefusion OCs (preOCs), resulting
in a reduced number of mature OCs. Furthermore, high
NINJ1 expression is associated with human bone dis-
orders, such as rheumatoid arthritis and postmenopausal
osteoporosis. Our ﬁndings suggest that Ninj1 has a novel
role in OC development and bone homeostasis and might
represent a potent therapeutic target for destructive bone
disorders.
Materials and methods
Reagents
Recombinant mouse M-CSF, GM-CSF, IL-4, and
RANKL were purchased from BioLegend (San Diego,
CA). AF488-phalloidin was purchased from Invitrogen
(Carlsbad, CA). Antibodies for immunoblot assays were
obtained against NFATc1 (Pierce, Rockford, IL); Oscar
(R&D Systems, Minneapolis, MN); TRAP (BioLegend);
Integrin β3; c-Fos; cleaved Caspase-3, -8, and -9; and
cleaved PARP (Cell Signaling Technology, Mountain
View, CA). The previously described anti-Ninj1 Ab1-15
18
was used for immunoblotting assays. For FACS analysis,
Fc block, and PE-anti-mouse CD115, APC-anti-mouse
CD117, and V450-anti-mouse CD11b antibodies were
purchased from BD Biosciences (Bedford, MA), and
biotin-anti-RANK antibody and APC/Cy7 streptavidin
were obtained from BioLegend.
Mice and bone analysis
Ninj1−/− mice were described previously18. All animal
studies were performed with male mice to exclude sex
hormonal effects. Bone marrow cells were obtained from
femurs and tibias of 7-week-old Ninj1−/− mice or their
wild-type (WT) littermates and used for differentiation
into macrophages or OCs. Hind limbs isolated from 6- or
12-week-old mice were scanned individually with a radi-
ology apparatus. Plain radiologic and μCT images were
obtained with an IVIS Spectrum CT (PerkinElmer,
Waltham, MA) and Quantum GX μCT (PerkinElmer) at
10-μm isotropic resolution, respectively. Trabecular bone
samples with lengths of over 1 mm encompassing the
region of the distal metaphysis away from the proximal
edge of the growth plate in the distal end of femurs were
analyzed using Inveon Research Workplace (Siemens,
Malvern, PA).
All mice were housed in the animal care facility of Seoul
National University under speciﬁc pathogen-free condi-
tions, and all animal procedures were approved by the
Institutional Animal Care and Use Committees of Seoul
National University.
In vitro osteoclastogenesis
Bone marrow-derived macrophages (BMMs) were
obtained by bone marrow cell culture. Brieﬂy, bone
marrow cells were isolated by ﬂushing the diaphysis of
femurs and tibias with phosphate-buffered saline (PBS)
and incubated overnight in α-modiﬁed Eagle’s medium
(MEM) supplemented with 10% fetal bovine serum (FBS)
to remove nonhematopoietic lineage cells. Floating cells
were further incubated in α-MEM supplemented with
10% FBS and M-CSF (30 ng/mL). After 3 days, non-
adherent cells were removed, and BMMs were used as OC
precursors. For OC generation, BMMs were further cul-
tured in α-MEM supplemented with 10% FBS and M-CSF
(30 ng/mL) and RANKL (100 ng/mL) for the indicated
days. Mouse macrophage/preOC RAW264.7 cells were
purchased from the Korean Cell Line Bank (Seoul, Korea)
and maintained in Dulbecco’s MEM with 10% FBS.
For OC differentiation, RAW264.7 cells were cultured in
α-MEM supplemented with 10% FBS and RANKL
(30 ng/mL).
TRAP activity staining and measurement of TRAP activity
Tartrate-resistant acid phosphatase (TRAP) activity was
assessed using a TRAP Staining Kit (Kamiya Biomedical
Company, Tukwila, WA) according to the manufacturer’s
protocol. Following colorization, TRAP-positive multi-
nucleated cells (≥3 nuclei) were counted, and images were
obtained with an Axiocam MRc on an Axiovert 200M
microscope (Zeiss, Oberkochen, Germany). For TRAP
activity measurements in conditioned media, OC culture
media were refreshed 24 h prior to collection on the
indicated days and immediately centrifuged to remove cell
debris, and supernatants were incubated with the chro-
mogenic substrates in tartrate-containing buffer for 3 h at
37 °C. For lysates, cells were lysed in an extraction buffer
containing 100mM Tris pH 8.0, 150mM NaCl, 1% NP-
40, and proteinase inhibitor cocktail (Calbiochem, San
Diego, CA). Following incubation, residual activity was
inhibited by 4% NaF for 30min, and absorbance at
540 nm was measured using a microplate reader (Spectra
Fluor; Tecan, San Jose, CA).
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FACS analysis
To identify OC progenitor cells, bone marrow cells were
incubated with mouse Fc Block (anti-mouse CD16/CD32)
in 3% bovine serum albumin (BSA)/PBS for 30min. The
cells were then stained with PE-anti-mouse CD115, APC-
anti-mouse CD117, and V450-anti-mouse CD11b anti-
bodies for 1 h and analyzed via FACS. To characterize OC
precursors, BMMs were preincubated with mouse Fc
Block and streptavidin in 3% BSA/PBS for 30min. Sub-
sequently, the cells were stained with PE-anti-mouse
CD115, V450-anti-mouse CD11b, and biotin-anti-RANK
antibodies followed by incubation with APC/
Cy7 streptavidin and subjected to FACS analysis. To
discriminate apoptotic cells, BMMs cultured with M-CSF
and RANKL were collected and stained with FITC-
Annexin V and 7AAD on the indicated days with sub-
sequent FACS analysis. All assays were performed using
FACSVerse and analyzed with FACSuite 1.0.5 (BD
Biosciences).
Confocal microscopy
To visualize the multinucleated giant cells, BMMs were
cultured on glass coverslips with M-CSF (50 ng/mL)+ IL-
4 (100 ng/mL) or GM-CSF (50 ng/mL)+ IL-4 (100 ng/
mL). At day 6, cells were washed with PBS and stained
with carboxyﬂuorescein succinimidyl ester (CFSE, 5 μM)
for 5 min. Subsequently, cells were ﬁxed with 4% paraf-
ormaldehyde and counterstained with Hoechst 33342. To
assess preOC transmigration, BMMs were retrovirally
transduced with Lifeact-mCherry (see Supplementary
materials and methods). Transduced BMMs were selected
and further cultured with M-CSF (30 ng/mL) and RANKL
(100 ng/mL) for 3 days. Then, the cells were detached and
overlaid on a conﬂuent monolayer of GFP-expressing
MC3T3-E1 cells. Serial images were stacked over 10- to
14-μm depths in 0.4-μm intervals. To measure actin ring
cytoskeletons and OC size, BMMs were cultured on glass
coverslips with M-CSF (30 ng/mL) and RANKL (100 ng/
mL) for 6 days and ﬁxed with 4% PFA. Following per-
meabilization with 0.05% Triton X-100, the cells were
stained with AF488-phalloidin to visualize F-actin. The
area surrounded by the actin ring cytoskeleton was cal-
culated using ImageJ 1.47t (National Institutes of Health,
Bethesda, MD). All images, including Z-plane images,
were obtained using an LSM 700 confocal microscope
(Zeiss) and processed using ZEN 2012 software (Zeiss).
Microarray analysis
We compiled 4 publicly available gene expression data
sets (accession nos. GSE1964, GSE7158, GSE7524 and
GSE27390) of human samples from Gene Expression
Omnibus (GEO). Raw feature data from 3 data sets
(GSE7158, GSE7524, and GSE27390) were normalized
using the MAS5 method (R package affy). Dataset
GSE1964 was downloaded from GEO as already nor-
malized. The average expression values were calculated
for samples. NINJ1 gene with an absolute fold change of
least 1.3 between compared groups was assigned as dif-
ferentially expressed. To evaluate statistical signiﬁcance
between the compared groups, a t test was applied
using SigmaPlot version 12.5.0. (Systat Software Inc.,
San Jose, CA).
Statistical analysis
The data are presented as the means ± SD and were
calculated and analyzed with SigmaPlot 12.5.0. (Systat
Software Inc., San Jose, CA). Two-tailed Student’s t test
was used to determine the signiﬁcance of differences
between two groups. The data in Figs. 4c and 5b were
analyzed with a Mann-Whitney U test. The data in Fig. 8c,
d were analyzed using a paired t test and one-tailed Stu-
dent t test, respectively. Differences with P < 0.05 were
considered signiﬁcant.
Results
Ninj1 deletion enhances trabecular bone volume in mice
We ﬁrst found that Ninj1 is highly expressed in mature
OCs (Supplementary Fig. S1a), suggesting its involvement
in bone homeostasis regulation in vivo. Assessment of the
hind limbs of 6- or 12-week-old Ninj1−/− mice by plain
radiology indicated that the metaphysis and diaphysis
intensities were stronger than those of WT littermates.
Furthermore, femur morphologies were linear rather than
concave (Fig. 1a). To investigate Ninj1 deﬁciency-
associated bone abnormalities, we compared distal
femurs and proximal tibias from 6- or 12-week-old WT
and Ninj1−/− male mice by μCT analysis. As expected, a
clear trabecular bone mass increase was observed in both
bones of the Ninj1−/− mice (Fig. 1b, Supplementary Fig.
S1b). Quantitative measurements revealed increases in
bone parameters such as the trabecular tissue volume
(Bone Volume/Total Volume), thickness, and number in
Ninj1−/− mice. In contrast, bone surface area (Bone
Surface Area/Bone Volume) and the space between tra-
becular architectures (Trabecular Spacing) were
decreased (Fig. 1c, Supplementary Fig. S1c). These data
indicate that Ninj1 deﬁciency in mice stimulates a mild
osteopetrotic phenotype in long bones.
Then, we assessed Ninj1 expression during OC devel-
opment because in preliminary experiments the expres-
sion level of Ninj1 was signiﬁcantly higher in OCs than in
the OB cell line MC3T3-E1 (Supplementary Fig. S2).
Ninj1 was upregulated from days 0 to 2, downregulated at
days 3 and 4, and restored from days 5 to 7 in BMMs
cultured with M-CSF and RANKL (Fig. 1d). In addition,
Ninj1 expression in RAW264.7 cells was dose-
dependently increased by RANKL (Supplementary
Fig. S3a). Collectively, these data suggest that Ninj1
Bae et al. Experimental & Molecular Medicine (2019) 51:7 Page 3 of 16
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
deletion in mice leads to increased trabecular bone
volume through modulation of OC development.
Ninj1 deﬁciency reduces multinucleated OCs
We then investigated whether the mild osteopetrotic
phenotype of Ninj1−/− mice represents a defect in OC
development. Bone marrow cells from WT and Ninj1−/−
mice were cultured with M-CSF and RANKL and stained
for TRAP activity. TRAP+ multinucleated cell number
and size were signiﬁcantly decreased in Ninj1−/− cells
(Fig. 2a, b). Similar results were obtained in RAW264.7
cells treated with Ninj1 siRNA (Supplementary
Fig. S3b–d). Next, we examined typical OC differentiation
marker expression. Notably, Nfatc1 and c-Fos, transcrip-
tion factors for OC differentiation, were unchanged at day
2 and the expression of other OC-speciﬁc genes, including
Itgb3, Oscar, and Calcr, was comparable in Ninj1−/− cells
(Fig. 2c, d), suggesting that Ninj1 deﬁciency disturbs OC
development independent of the differentiation process.
Ninj1 deletion augments OC progenitors
The proportion of OC progenitors in the bone marrow
is important in the early stage of osteoclastogenesis19.
Because decreased multinucleated OCs might result from
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Fig. 1 Ninj1−/− mice show mild osteopetrosis, and Ninj1 is expressed in osteoclasts. a Representative plain X-ray images of hind limbs from
Ninj1−/− 6- or 12-week-old mice and their corresponding WT littermate mice. b Representative μCT images of distal femurs from Ninj1−/− 6- or 12-
week-old mice and their corresponding WT littermate mice. Scale bars, 1 mm. c μCT-determined trabecular bone parameters of distal femurs from 6-
or 12-week-old WT (n= 5, and n= 4, respectively) and Ninj1−/− mice (6-week-old; n= 7, 12-week-old; n= 6). d Ninj1 expression during osteoclast
development. Quantitative data are shown as the mean ± SD, *P < 0.05, **P < 0.01, and ***P < 0.001
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reduced progenitor cell numbers, we analyzed the OC
progenitor proportion in bone marrow cells fromWT and
Ninj1−/− mice via ﬂuorescence-activated cell sorting
(FACS). Csf1r+ cells were gated ﬁrst and further analyzed
for c-Kit and Cd11b expression (Fig. 3a). Notably, OC
progenitors were 1.37-fold more abundant in Ninj1−/−
mice (Fig. 3b). The expression of M-CSF receptor and
RANK in OC precursors is important for early osteo-
clastogenesis19,20. Thus, we evaluated BMMs, which are
used as OC precursors in vitro. FACS and immunoblot
analyses indicated that Csf1r, Rank, and Cd11b expression
levels were comparable between groups (Fig. 3c, Supple-
mentary Fig. S4).
OCs transmigrate to the OB layer to adhere to miner-
alized matrix7. We previously reported that Ninj1
enhances macrophage transendothelial cell migration21.
To address this possibility in OCs, we compared the
preOC transmigration capabilities22,23. BMMs were
transduced with Lifeact-mCherry and cultured with M-
CSF and RANKL for 3 days to generate mononuclear
preOCs. Then, the cells were replaced on a conﬂuent
monolayer of OB-like MC3T3-E1 cells expressing GFP.
During continuous culture with osteoclastogenic cyto-
kines, Z-plane images were acquired after 30 min or 12 h
by confocal microscopy. Both groups of preOCs trans-
migrated completely through the OB layer and spread
well (Fig. 3d). Collectively, these data suggest that Ninj1 is
dispensable for OC precursor differentiation and preOC
transmigration but might negatively modulate OC pro-
genitor development in mice.
Macrophage fusion is enhanced by Ninj1 deﬁciency
Mononuclear cell fusion is a critical step in OC devel-
opment, and defective preOC fusion stimulates osteope-
trosis in mice24. Following the exclusion of defective
migration in Ninj1−/− cells, which could affect the fusion
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Fig. 2 Ninj1 deﬁciency reduces multinucleated osteoclasts, which is not related to defective differentiation. a, b WT and Ninj1−/− bone
marrow cells were cultured with M-CSF for 3 days, and nonadherent cells were discarded. Adherent cells were continuously cultured with M-CSF and
RANKL for 7 additional days and subjected to TRAP activity staining. a Representative images of TRAP activity staining. Scale bars, 200 μm.
b Quantitation of TRAP-positive multinucleated osteoclasts. Numbers of TRAP-positive multinucleated osteoclasts (TRAP+ MNCs, ≥ 3 nuclei) are
shown as the mean ± SD; ***P < 0.001. c, d The expression of Ninj1 and osteoclast markers during osteoclastogenesis was analyzed by quantitative
RT-PCR (c) or immunoblot assays (d). c The mRNA expression of Ninj1 and osteoclast markers, including Nfatc1, c-Fos, Itgb3, Oscar, and Calcr, was
analyzed, and relative mRNA expression levels are shown as the mean ± SD; *P < 0.05, **P < 0.01, and ***P < 0.001. d Protein expression of Ninj1 and
osteoclast markers
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capacity of myeloid cells, we suspected that Ninj1 deﬁ-
ciency interrupted cell–cell fusion itself. Accordingly, we
cultured BMMs with M-CSF+ IL-4 or GM-CSF+ IL-4
for 6 days25. Multinucleated giant cells and their nuclei
were slightly increased in Ninj1−/− cells cultured with M-
CSF+ IL-4, whereas in GM-CSF+ IL-4 culture, 1.44-fold
more multinucleated giant cells and signiﬁcant nuclei
increases were observed (Fig. 4). Because Ninj1 deﬁciency
might affect the efﬁcacy of IL-4 in macrophages, we
assessed Arginase-1 induction by IL-4 in BMMs; however,
no between-group differences were observed (Supple-
mentary Fig. S5a). In addition, preOC migration and/or
fusion-associated genes were signiﬁcantly increased dur-
ing osteoclastogenesis (Supplementary Fig. S5b). As
(see ﬁgure on previous page)
Fig. 3 Analysis of osteoclast progenitor cells in the bone marrow, typical marker expression in macrophages, and transmigration of
preOCs. a, b Bone marrow cells were analyzed by FACS. a Representative density plots of Csf1r+ bone marrow cells. b The percent frequency of
osteoclast progenitor cells (red box, Csf1r+c-Kit+Cd11bdull) in (A) is shown as the mean ± SD; *P < 0.05. c BMMs were analyzed by FACS. The
expression of Csf1r is shown in whole cells (left), and Csf1r+-gated cells were analyzed for Rank ((y-axis) and Cd11b ((x-axis) expression (right). d BMMs
transduced with Lifeact-mCherry were cultured with M-CSF and RANKL for 3 days to generate preOCs. Lifeact-mCherry-labeled preOCs were overlaid
on a GFP+ MC3T3-E1 osteoblast monolayer with the continued presence of osteoclastogenic cytokines. Z-plane images were acquired after 30 min
(upper) or 12 h (lower) via confocal microscopy. Scale bars, 10 μm
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Fig. 4 Ninj1−/−macrophages generate more multinucleated giant cells. a, c Multinucleated giant cells were induced by culturing BMMs with M-
CSF+ IL-4 (left) or GM-CSF+ IL-4 (right) followed by staining with CFSE (green) and Hoechst (red). (a) Representative images of giant cells. Scale bars,
100 μm. b Numbers of multinucleated cells are shown as the mean ± SD; ***P < 0.001. c Numbers of nuclei in multinucleated cells are presented in a
median-quartile boxplot; *P < 0.05
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accelerated myeloid cell fusion reduces bone mass by
improving osteoclastogenesis26,27, these results suggest
that enhanced Ninj1−/− cell fusion might counteract
osteopetrotic severity in Ninj1−/−mice and that Ninj1 has
an inhibitory role in myeloid cell fusion.
Ninj1 deletion reduces mature OC area and attenuates
TRAP activity in culture medium
The OC actin ring cytoskeleton isolates the degradative
microenvironment from the general extracellular space;
failure of actin ring formation contributes to osteopetrosis
development28. Thus, we assessed actin cytoskeletons in
mature OCs. BMMs were cultured with M-CSF and
RANKL on glass coverslips. After 6 days, the cells were
stained with phalloidin to visualize F-actin. However,
actin ring appearance was indistinguishable between
Ninj1−/− and WT OCs, with similar proportions of actin
ring-forming cells (Fig. 5a). Conversely, mature Ninj1−/−
OCs were smaller than WT OCs, exhibiting a 0.73-fold
smaller area surrounded by the actin ring (Fig. 5b). As
Ninj1−/− myeloid cells showed no defect in cell–cell
fusion or actin ring formation, these data suggest that the
area reduction in Ninj1−/− OCs might be associated with
a diminished preOC cell population.
Bone matrix resorption is a novel OC function dependent
upon degradative enzyme quantity and mobilization29. Spe-
ciﬁcally, TRAP directly reﬂects OC resorptive function30.
Thus, we assessed TRAP activity during OC development by
culturing BMMs with M-CSF and RANKL31,32. Conditioned
medium TRAP activities were signiﬁcantly reduced in
Ninj1−/− culture (Fig. 5c), whereas cell lysate activities were
comparable to WT (Fig. 5d). In addition, similar TRAP and
other OC enzyme mRNA expression patterns, including
those of Cathepsin K and MMP-9, were found (Fig. 5e). This
discordance in TRAP activity in Ninj1−/− cell culture med-
ium reﬂects reduced numbers of TRAP-producing cells.
Together, these data suggest that Ninj1−/− cells dropped out
prior to OC maturation and that Ninj1 might be important
for cell population maintenance.
Ninj1 enhances preOC survival during osteoclastogenesis
Collectively, the previous data suggest that Ninj1 deﬁ-
ciency might inﬂuence the cell population by modulating
proliferation and/or survival. OC number is inﬂuenced by
precursor cell propagation and precursor, prefusion, and
mature OC death. Thus, we monitored the cell population
following M-CSF and RANKL treatment singly or in
combination. Ninj1−/− BMMs expanded more in culture
with M-CSF (Supplementary Fig. S6a) and grew faster
during the ﬁrst 2 days than WT cells with combination
treatment. However, from day 2 to day 4, Ninj1−/− cells
diminished rapidly (Fig. 6a). Neither phenomenon was
observed upon RANKL treatment (Fig. 6b). These data
indicate that M-CSF-dependent Ninj1−/− myeloid cell
ampliﬁcation might ameliorate mature OC reduction
in vitro and increase trabecular bone volume in vivo and
that the Ninj1−/− cell reduction is related to osteoclas-
togenic conditions.
To determine whether the population diminishment is
related to apoptosis, cells stained with Annexin V and
7AAD were analyzed by FACS. Ninj1−/− cell Annexin V+
populations were 1.82-, 1.75-, and 1.51-fold greater than
those of WT cells at days 2, 3, and 4, respectively; over
half of Annexin V+ cells were also 7AAD+, indicating
irreversible apoptosis (Fig. 6c–e). Similar results were
obtained in RAW264.7 cells at days 2 and 3 (1.61- and
1.90-fold increase, respectively) following Ninj1 siRNA
treatment (Fig. 6f–h). Furthermore, RANKL but not TNF-
α speciﬁcally increased apoptosis in Ninj1-deﬁcient cells
(Supplementary Fig. S6b–e). These results indicate that
Ninj1 sustains preOC survival and inhibits apoptosis fol-
lowing OC differentiation.
Ninj1 deﬁciency induces Caspase-9-dependent intrinsic
apoptosis in preOCs
The intrinsic and extrinsic apoptosis pathways are
initiated by pro- or antiapoptotic protein dysregulation or
liganded death receptors, respectively, followed by
sequential activation of Caspase-9 and Caspase-3 or
Caspase-8 and Caspase-333,34. To identify the type of
apoptosis induced by Ninj1 deﬁciency, cell lysates from
BMMs cultured with M-CSF and RANKL were immu-
noblotted. Cleaved Caspase-3 was observed from day 2 in
Ninj1−/− cells and was augmented following differentia-
tion. Notably, cleaved Caspase-9 but not cleaved Caspase-
8 was observed with cleaved Caspase-3 and cleaved PARP
in Ninj1−/− cells (Fig. 7a). Similarly, Caspase-9 and
Caspase-3 active forms were stronger in siNinj1-
transfected vs. control RAW264.7 cells without cleaved
Caspase-8 detection (Fig. 7b). To determine whether
Ninj1-deﬁcient cell apoptosis might affect neighboring
cell viability or was cell-autonomous, GFP- or DsRed-
labeled RAW264.7 cells were transfected with siScr or
siNinj1 and an equal number of GFP+ or DsRed+ trans-
fectants were cultured together with RANKL. The ratio of
GFP+ to DsRed+ cells indicated that neither siNinj1 nor
control transfectants impacted the respective viability of
the other (Fig. 7c, Supplementary Fig. S7a,b). To ascertain
whether an increase in Ninj1 expression would attenuate
spontaneous apoptosis during osteoclastogenesis, we
transduced RAW264.7 cells with Ninj1-FLAG and fol-
lowing RANKL treatment examined apoptosis via FACS.
Annexin V+ cells were 0.66- and 0.55-fold reduced by
Ninj1 overexpression at days 2 and 3, respectively
(Fig. 7d–f, Supplementary Fig. S7c). Collectively, these
data indicate that Ninj1 is a prerequisite for preventing
Caspase-9-dependent apoptosis induction in preOCs and
that Ninj1 upregulation enhances preOC survival.
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High NINJ1 expression is correlated with human bone
disorders
To investigate the potential association between NINJ1
expression and bone disorders in humans, we mined
publicly available data sets in GEO and analyzed four
different microarrays. Gene expression proﬁles of 10
patients with osteoarthritis (OA) and 9 with rheumatoid
arthritis (RA) demonstrated signiﬁcantly elevated NINJ1
expression in RA (1.99-fold compared with OA, Fig. 8a).
Furthermore, comparison of NINJ1 expression in 8
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Fig. 5 Ninj1-deﬁcient osteoclasts have a smaller area surrounded by an actin ring, and TRAP activity is reduced in Ninj1−/− cell culture
medium. a, b BMMs were cultured on glass coverslips with M-CSF and RANKL for 6 days. Cells were stained with AF488-Phalloidin. a Representative
images of osteoclasts with actin ring formation (left) and highly magniﬁed images of the insets on the left (right). Scale bars, 50 μm. b The area inside
the actin ring formed in osteoclasts is shown in a median-quartile boxplot; *P < 0.05. c, d BMMs were cultured with M-CSF and RANKL for the
indicated days. Absorbance at 540 nm was measured to assess TRAP activity. c Conditioned medium was collected on the indicated days and
subjected to a TRAP activity assay. The absorbance is shown as the mean ± SD (n= 3, with triplicates in each experiment); ***P < 0.001. d Cell lysates
were harvested on the indicated days and subjected to a TRAP activity assay. The absorbance is shown as the mean ± SD (n= 3, with triplicates in
each experiment); **P < 0.01. e mRNA expression of resorption-related osteoclast markers, including TRAP (Trap), Cathepsin K (Ctsk) and MMP-9
(Mmp9), was analyzed by quantitative RT-PCR. The relative mRNA expression is shown as the mean ± SD; *P < 0.05, and **P < 0.01
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patients with RA and 15 with early RA revealed a 2.60-
fold enhancement in early RA, suggesting that NINJ1 is
important for RA onset (Fig. 8b). Following three months
of anti-TNF (Enbrel) therapy in 2 patients with RA, NINJ1
expression was signiﬁcantly reduced (0.46-fold vs. pre-
treatment, Fig. 8c). Furthermore, postmenopausal women
with low peak bone mass (n= 7) exhibited 1.40-fold
higher NINJ1 expression than those with high peak bone
mass (n= 8), suggesting that NINJ1 might be associated
with osteoporotic bone loss (Fig. 8d). Together, these data
suggest that NINJ1 has a potent role in human bone
disorder pathogenesis and/or progression.
Discussion
The current study investigated the role of Ninj1 in OC
development and cell survival maintenance, providing the
ﬁrst evidence that Ninj1 is important for bone home-
ostasis by sustaining preOC survival. We show that Ninj1
is highly expressed in OCs differentiated from bone
marrow and that OC and macrophage Ninj1 expression is
comparable. Plain X-ray images demonstrated strong hind
limb intensity and linear rather than concave femur dia-
physis morphology in Ninj1−/− mice, which are novel
signs of osteopetrosis35. μCT analysis further demon-
strated increased femoral and tibial trabecular bone mass
in Ninj1−/− mice, which was prolonged from 6- to 12-
weeks. Ninj1−/− mice have been reported to be small and
have several skeletal deformities, such as an asymmetric
face or dome-shaped head, and often develop hydro-
cephalus14,36, which is frequently developed in patients
with autosomal recessive osteopetrosis8,37. In addition,
Ninj1−/− mice frequently exhibit vertebral column
(kyphosis or scoliosis) and orbital bone (cyclopia) defor-
mities and often show cycling behavior, suggesting the
possibility of defective ossicles and/or cochlea (unpub-
lished observations). Collectively, these data suggest that
Ninj1 might impact bone homeostasis by modulating OC
development and/or function.
OCs accomplish bone resorption through several con-
tinuous processes: (1) OC progenitor/precursor cell
development from hematopoietic stem cells, (2) OC pre-
cursor proliferation, (3) OC precursor differentiation into
mononuclear preOCs, (4) preOC fusion into multi-
nucleated OCs, (5) attachment to calciﬁed matrix and OC
polarization followed by matrix degradation, and ﬁnally
(6) death by apoptosis38. Our data show that Ninj1 deﬁ-
ciency reduces the number of TRAP+ multinucleated
OCs derived from bone marrow cells but does not impact
differentiation into OCs as deﬁned by OC marker
expression, suggesting that Ninj1 deﬁciency only mini-
mally disrupts major OC differentiation signaling path-
ways, such as MAPK, AP-1, NFκB, and NFATc139.
Therefore, the reduction in mature OCs might result from
a decreased proportion or quality of OC progenitor cells
in the bone marrow, which are derived from hemato-
poietic stem cells that give rise to common lymphoid and
myeloid progenitors in response to various factors40.
Accordingly, M-CSF, PU.1, MITF, and Bcl-2 mutation
lead to osteopetrosis in mice resulting from reduced OC
progenitor cells41. Speciﬁcally, c-Kit+c-Fms+CD11bdull
cells are potent bone marrow OC progenitor cells that
effectively differentiate into OCs19. However, c-Kit+c-
Fms+CD11bdull OC progenitor cells are clearly increased
in Ninj1−/− mice. Nonetheless, whereas we previously
showed similar peripheral blood cell composition in
Ninj1−/− and WT mice via complete blood counts, the
differential count identiﬁed a trend toward myeloid cell
increase, including neutrophils (1.28-fold) and monocytes
(1.33-fold)14. Combined with the current observations,
these data suggest that Ninj1 might instead have a potent
role in myelopoiesis. Finally, the essential osteoclastogenic
cytokines M-CSF and RANKL bind M-CSF receptor and
RANK, respectively, on OC precursors, and their targeted
deletion leads to osteopetrosis in mice caused by OC
differentiation failure42–44. However, our data show that
Csf1r, Rank, and Cd11b expression in BMMs is indis-
tinguishable between genotypes, indicating that Ninj1−/−
OC precursor cells develop normally from myeloid pro-
genitors and implying that Ninj1 deﬁciency might affect a
later stage of osteoclastogenesis.
OC precursors exposed to M-CSF and RANKL differ-
entiate into mononuclear preOCs followed by mono-
nuclear cell fusion to generate multinucleated
osteoclasts6. Disruption of cell fusion through genetic
(see ﬁgure on previous page)
Fig. 6 Ninj1 deﬁciency induces apoptosis during osteoclastogenesis. a BMMs were cultured with M-CSF and RANKL. The absorbance induced by
MTS was measured at 492 nm, and the relative cell population is shown as the mean ± SD (n= 3, with triplicates in each experiment); **P < 0.01.
b BMMs were cultured with RANKL, and the relative cell growth was evaluated at the indicated time points and is shown as the mean ± SD (n= 3,
with triplicates in each experiment). c–e BMMs were cultured with M-CSF and RANKL. Cells were harvested and stained with FITC-Annexin V and
7AAD on the indicated days followed by FACS analysis. c Representative density plots at days 2 and 4. (d) FACS-determined statistical stacked bars (n
= 4). (e) The FACS-determined percent frequencies of Annexin V+ cells are shown as the mean ± SD (n= 4). (f–h) RAW264.7 cells were transfected
with siScr or siNinj1 and cultured with RANKL. Cells were harvested and stained with FITC-Annexin V and 7AAD on the indicated days followed by
FACS analysis. (f) Representative density plots at days 2 and 3 determined by FACS analysis. (g) FACS-determined statistical stacked bars (n= 4).
(h) FACS-determined percent frequency of Annexin V+ cells. The data are shown as the mean ± SD (n= 4); ***P < 0.001
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ablation of ATP6v0d245 or DC-STAMP46, which are
suspected to be involved in cell–cell recognition47, results
in severe osteopetrosis in mice due to multinucleated
osteoclast deﬁciency. As Ninj1 is a homophilic adhesion
protein12, Ninj1 deﬁciency might also disrupt cell–cell
recognition and fusion. However, Ninj1−/− BMMs fuse
more efﬁciently than WT BMMs, especially in culture
with GM-CSF+ IL-4. Furthermore, the expression of
several motility- and fusion-associated genes was
enhanced in Ninj1−/− cells, and transmigration
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Fig. 8 The expression level of NINJ1 is correlated with bone disorders in humans. a–d Expression levels of NINJ1 mRNA were analyzed from the
gene expression data sets GSE27390 (a), GSE1964 (b), GSE7524 (c) and GSE7158 (d) deposited in GEO. Red bars indicate the mean value. a Bone
marrow-derived mononuclear cells were obtained from patients with osteoarthritis (n= 10) or rheumatoid arthritis (n= 9), and NINJ1 mRNA
expression was analyzed. The data are shown in a median-quartile boxplot; *P < 0.05. b Comparison of NINJ1 expression in peripheral blood
mononuclear cells derived from patients with rheumatoid arthritis (n= 8) or early rheumatoid arthritis (n= 15). The data are shown in a median-
quartile boxplot; **P < 0.01. c The change in NINJ1 mRNA expression in whole blood samples from rheumatoid arthritis patients following anti-TNF
therapy was analyzed, and the data are shown as the mean ± SD (n= 2); *P < 0.05. d The difference in NINJ1 mRNA expression in circulating
monocytes derived from postmenopausal women with high (n= 8) and low (n= 7) peak bone mass was analyzed, and the data are shown in a
median-quartile boxplot; *P < 0.05
(see ﬁgure on previous page)
Fig. 7 Ninj1 suppresses Caspase-9-dependent intrinsic apoptosis in preOCs, and incremental Ninj1 expression enhances the survival of
preOCs. a BMMs were cultured with M-CSF and RANKL for the indicated days. Cell lysates were subjected to immunoblot analysis. b RAW264.7 cells
transfected with siScr or siNinj1 were cultured with RANKL. Cells were harvested on the indicated days and subjected to immunoblot assays. c GFP+
or DsRed+ RAW264.7 cells were transfected with scrambled siRNA or Ninj1 siRNA as indicated. An equal number of each ﬂuorescence protein-labeled
cell population was cocultured with RANKL. The ratio of GFP+ to DsRed+ cells was determined using FACS, and the data are shown as the mean ± SD
(n= 3, with triplicates in each experiment); **P < 0.01, and ***P < 0.001. d–f RAW264.7 cells were stably transduced with Ninj1-FLAG or empty vector
using a retrovirus and cultured with RANKL. Cells were harvested and stained with APC-Annexin V and 7AAD on the indicated days followed by FACS
analysis. d Representative plots showing the results of FACS analysis on days 2 and 3. e FACS-determined statistical stacked bars (n= 4). f FACS-
determined percent frequency of Annexin V+ cells. The data are shown as the mean ± SD (n= 4); **P < 0.01
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capabilities were indistinguishable between genotypes,
suggesting that Ninj1 is dispensable for preOC migration
and fusion. Additionally, the frequency of multinucleated
cells with an actin ring cytoskeleton and the actin ring
morphologies are indistinguishable between WT and
Ninj1−/− cells. Conversely, the area enclosed by the actin
ring is signiﬁcantly reduced in Ninj1−/− OCs, suggesting
that the participant mononuclear preOC numbers might
be decreased by Ninj1 deﬁciency prior to this stage. The
signiﬁcant reduction in TRAP activity in the Ninj1−/− cell
conditioned medium but not in cell lysate indicates that
Ninj1 deletion might alter the cell population by mod-
ulating proliferation and/or survival.
Aberrant OC apoptosis leads to bone homeostasis dysre-
gulation and bone disease. OC apoptosis is lower in osteo-
porotic bone and evident in the late stage of Paget’s bone
disease, which manifests as sclerotic bone lesions48. Our data
revealed that Ninj1 deﬁciency induces Caspase-9-dependent
intrinsic apoptosis in both primary and RAW264.7 cells in a
cell-autonomous manner. Ninj1 reduction accompanied
apoptotic features in WT preOCs, and Ninj1 overexpression
in RAW264.7 cells reduced this spontaneous apoptosis in
osteoclastogenic culture. Thus, during osteoclastogenesis, the
Ninj1 level inﬂuences preOC survival, with deﬁciency
exacerbating apoptosis. Conversely, loss of Ninj1 in BMMs
accelerates M-CSF-induced cell proliferation. The novel role
of Ninj1 in OC/macrophage precursor cell propagation
needs to be elucidated.
Recently, a protective role of Ninj1 against different
types of cell death was reported. Ninj1 inhibited p53-
dependent cellular senescence by reducing p53 transla-
tion, potentially regulated by mechanistic targeting of
rapamycin (mTOR) kinase36,49. M-CSF and RANKL
promoted OC survival through mTOR kinase by down-
regulating the expression of Bim, a downstream effector
of PI3K50,51. Conversely, p53 inhibited mTOR, resulting
in suppression of cell survival52,53. Furthermore, p53−/−
mice exhibit increased OC number and bone resorption54.
Thus, Ninj1 might potentially enhance preOC survival by
intervening in p53-mTOR kinase crosstalk. Considering
its role as a c-Jun-regulated antiapoptotic gene, apoptosis
was induced by Ninj1 downregulation in triple-negative
breast cancer cells and further accelerated by TNF-α,
whereas Ninj1 overexpression ameliorated TNF-α-
induced apoptosis in c-Jun knockdown cells55. However,
in our study, TNF-α did not induce apoptosis in Ninj1-
deﬁcient RAW264.7 cells; this discrepancy might result
from different TNF receptor occupancy in immune cells.
Nevertheless, our data support the protective role of Ninj1
against various types of cell death.
Decreased OC apoptosis is implicated in destructive
bone diseases, such as RA and osteoporosis56. In bone
destructive disorders, TNF-α is commonly elevated and
participates in progressive bone resorption57. Increased
TNF-α enhances the survival and differentiation of
osteoclasts50, which exacerbates bone loss, and blockade
of TNF-α provides a powerful therapeutic strategy for
bone destructive disorders58,59. Our data show that not
only RANKL but also TNF-α upregulated Ninj1 expres-
sion in BMM. In addition, increased Ninj1 expression
ameliorated spontaneous apoptosis during osteoclasto-
genesis in RAW264.7 cells, and microarray analyses
revealed correlations between high NINJ1 expression and
the above disorders.
Moreover, an increase in Ninj1 might play a detrimental
role in destructive bone disorders as well as in other
pathologic conditions, such as diabetes mellitus60.
Accordingly, NINJ1 is associated with insulin insensitivity
and type 2 diabetes incidence in African Americans61. In
humans, diabetes elicits several metabolic and endocrine
alterations that result in osteoporosis62, and streptozoto-
cin induces osteoporosis following the occurrence of
diabetes in mice63. Therefore, an investigation into the
precise role of NINJ1 in bone homeostasis in metabolic
diseases such as diabetes might yield new insights into the
systemic regulation of bone metabolism.
The hallmark of OCs is their unique ability to resorb
mineralized calcium apatite or carbonate substrates in
bone7. However, in the current study, we primarily
focused on the role of Ninj1 in OC development. In our
mice, Ninj1 is ubiquitously deleted so that during in vitro
OC differentiation, most Ninj1−/− cells dropped out and a
few mature OCs remained. The failure to provide mature
OCs rendered deﬁning the role of Ninj1 in those cells
difﬁcult. Accordingly, stage-speciﬁc Ninj1 deletion might
extend the current ﬁndings to mature OCs.
This work presents several novel ﬁndings. First, Ninj1 is
highly expressed in OCs in contrast with OBs, and
Ninj1−/− mice show a mild osteopetrotic phenotype in
long bones. Second, Ninj1 deﬁciency reduces multi-
nucleated OC numbers. Third, Ninj1−/− preOCs are
vulnerable to Caspase-9-dependent intrinsic apoptosis.
Finally, high NINJ1 expression is correlated with human
bone disorders, such as RA and postmenopausal osteo-
porosis. These ﬁndings have illuminated a novel function
of Ninj1 in bone homeostasis, suggesting that Ninj1 is one
of the several molecular regulators of osteoclast devel-
opment and thus represents a potential therapeutic target
in human destructive bone disorders.
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